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Objective. NLRP12 mutations have been de-
scribed in patients affected with peculiar autoinflamma-
tory symptoms. This study was undertaken to charac-
terize NLRP12 mutations in patients with
autoinflammatory syndromes, particularly a novel mis-
sense mutation, p.D294E, affecting a protein sequence
crucial for ATP binding, which was identified in a
Caucasian family with familial cold-induced autoin-
flammatory syndrome in some family members.
Methods. Fifty patients were tested for NLRP12
mutations. A Caucasian family with the p.D294E mis-
sense mutation of NLRP12 in some family members was
clinically characterized. In vitro analysis of the effects of
the mutation on NF-B activity was performed in HEK
293 cells after cotransfection of the cells with a lucif-
erase NF-B–responsive element and mutant or wild-
type (WT) NLRP12 expression plasmids. NF-B activity
was also evaluated 24 hours after stimulation with
tumor necrosis factor  in monocytes from individual
family members carrying the mutation. Furthermore,
secretion of interleukin-1 (IL-1), production of reac-
tive oxygen species (ROS), and activation of antioxidant
systems in patient and healthy donor monocytes, under
resting conditions and after stimulation with pathogen-
associated molecular patterns (PAMPs), were also as-
sessed.
Results. In the family assessed, the p.D294E
mutation segregated in association with a particular
sensitivity to cold exposure (especially arthralgias and
myalgia), but not always with an inflammatory pheno-
type (e.g., urticarial rash or fever). In vitro, the mutant
protein maintained the same inhibitory activity as that
shown by WT NLRP12. Consistently, NLRP12-mutated
monocytes showed neither increased levels of p65-
induced NF-B activity nor higher secretion of IL-1.
However, the kinetics of PAMP-induced IL-1 secretion
were significantly accelerated, and high production of
ROS and up-regulation of antioxidant systems were
demonstrated.
Conclusion. Even with a variable range of associ-
ated manifestations, the extreme sensitivity to cold
represents the main clinical hallmark in an individual
carrying the p.D294E mutation of the NLRP12 gene.
Although regulation of NF-B activity is not affected in
patients, redox alterations and accelerated secretion of
IL-1 are associated with this mild autoinflammatory
phenotype.
Autoinflammatory syndromes are a group of
diseases characterized by recurrent episodes of systemic
inflammation that are accompanied by fever and often
associated with other clinical manifestations, such as
rash, serositis (peritonitis, pleuritis), lymphadenopathy,
arthritis, and systemic reactive amyloidosis as severe
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830long-term complications (1). Among the autoinflamma-
tory syndromes, cryopyrin-associated periodic syn-
dromes (CAPS) are conditions associated with muta-
tions of the NLRP3 gene, also known as CIAS1 or
PYPAF1, a key component of the inflammasome directly
involved in the mechanism of interleukin-1 (IL-1)
processing and secretion. CAPS include familial cold-
induced autoinflammatory syndrome (FCAS), Muckle-
Wells syndrome (MWS), and chronic infantile neuro-
logic, cutaneous, articular syndrome (CINCA syndrome)
(2,3). These disorders are associated with gain-of-
function NLRP3 heterozygous mutations, which deter-
mine an abnormal in vitro secretion of IL-1 by mono-
cytes (4). The specific inhibition of IL-1 leads to a
dramatic normalization of the inflammatory manifesta-
tions (5,6) as well as a strong reduction in IL-1
secretion (7).
In addition, heterogeneous clinical manifesta-
tions have been observed in several families with CAPS
(8), suggesting that modifier genes and/or environmental
factors are involved in the disease phenotype. Patients
with clinical manifestations attributable to CAPS but
without mutations at the NLRP3 locus have been de-
scribed and, in a subset of these NLRP3-negative pa-
tients, mutations in the NLRP12 gene, also known as
MONARCH-1 or PYPAF7, have recently been identified
(9).
The nucleotide binding domain leucine-rich re-
peat containing protein (NLRP) family, also known as
CATERPILLER (caspase activation and recruitment
domain, transcription enhancer, purine binding, pyrin,
lots of leucine repeats), is structurally characterized by a
tripartite architecture containing a central nucleotide
binding domain (NACHT or NOD), which exhibits
ATPase activity and regulates oligomerization, a specific
N-terminal effector domain for recruiting downstream
effector molecules, and a C-terminal portion consisting
of a variable series of leucine-rich repeats implicated in
mediating autoregulation, protein–protein interactions,
and/or pathogen-associated molecular pattern (PAMP)
sensing (10). In humans, at least 22 NLRP family
members have been found to play a central role in the
regulation of inflammatory and cell death responses,
during infections and in autoinflammatory disorders
(10). In particular, NLRP-12 acts as a negative regulator
of inflammation by suppressing both canonical and
noncanonical NF-B activation and subsequent produc-
tion of proinflammatory cytokines and chemokines
(11,12). In the present study, we describe an Italian
family, some of whose members had clinical features
consistent with FCAS, in whom a missense mutation of
the NLRP12 gene was found.
PATIENTS AND METHODS
Patients. A total of 50 patients who were negative for
mutations of NLRP3 were analyzed for mutations of NLRP12.
The patients screened in the NLRP12 mutational search
included 2 patients with a history of cold-induced urticarial
rash associated with inflammatory features (i.e., fever, arthral-
gias, and elevation of acute-phase reactants), 5 patients with a
clinical phenotype strongly consistent with MWS or CINCA
syndrome, including responsiveness to anti–IL-1 treatment, 11
patients who had already been screened for genes associated
with periodic fever (MEFV, MVK, and TNFRSF1A) and had
presented with at least 1 of the typical manifestations during
fever attacks (urticarial rash, hearing loss, and sensitivity to
cold), 12 patients with systemic-onset juvenile idiopathic ar-
thritis displaying a complete response to anti–IL-1 treatment
(13–15), and 20 patients with a history of cold-induced urti-
caria without evidence of features of inflammation.
Eighty healthy individuals of Italian origin, randomly
selected among blood donors at the Gaslini Institute, were
analyzed as healthy control subjects, after providing their agree-
ment on a proper consent form. The present study was
approved by the Gaslini Institute ethics committee (Genoa,
Italy).
Mutation screening. The sequence of the sole exon 3
of the NLRP12 gene was analyzed for mutations by polymerase
chain reaction (PCR) (Table 1), followed by direct sequencing
using BIG DYE (version 1.1; Applied Biosystems) and an
Applied Biosystems 3130 automated sequencer.
Constructs and transfections. The wild-type (WT)
sequences of NLRP12 complementary DNA (cDNA) were
obtained by PCR from a MGC commercial clone and inserted
into the pcDNA3.1 vector. Mutant NLRP12 constructs were
generated by site-directed mutagenesis starting from this same
construct, as described previously (16), using the oligonucleo-
tides 5-TCATCATCGAGGGCTTCGATG-3 and 5-
CATCGAAGCCCTCGATGATGA-3 to introduce the
p.Asp294Glu substitution.
Plating of HEK 293 cells (2  10
5) on 24-well plates
was performed at the same time as the transfection, using
Fugene 6 (Roche), following the manufacturer’s instructions.
NF-B activity was tested using a synthetic promoter from
Stratagene, consisting of several repetitions of the canonical
NF-B binding site, cloned upstream of the reporter luciferase
cDNA. Fifty nanograms of this construct and 5 ng of Renilla
luciferase reporter plasmid pRL-CMV (Promega), used as a
transfection efficiency control, were cotransfected together
with the expression vectors. In particular, 100 ng of IL-1
receptor–associated kinase 1 (IRAK-1) or myeloid differenti-
ation factor 88 (MyD88) expression vectors (a kind gift from
Dr. J. Tschopp, Lausanne, Switzerland), were used for induc-
tion of NF-B activity and were cotransfected with 150 ng of
either the NLRP12 plasmid or pcDNA3.1 empty vector. Each
experiment was performed in triplicate and repeated at least 3
times.
NF-B activation assay. NF-B activation was evalu-
ated on nuclear extracts of monocytes prepared from the
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were treated with 10 ng/ml tumor necrosis factor  (TNF;
R&D Systems) for 24 hours or left untreated. The TransAM
NF-B p65 kit (Active Motif) was used to assess possible
NF-B activation, with the primary NF-B p65 antibody
recognizing an epitope on p65 that becomes accessible only
when NK-B is activated and bound to its target DNA. The
anti-rabbit horseradish peroxidase–conjugated antibody that
was used as secondary antibody provides a sensitive colorimet-
ric readout that is easily quantified by spectrophotometry. The
adsorbance was read within 5 minutes at 450 nm, with an
optical reference wavelength of 655 nm. Raji nuclear extracts
(Active Motif) were provided as a positive control for NF-B
activation.
Pattern of IL-1 secretion. Blood samples were ob-
tained from patients with the NLRP12 mutation and from 10
age-matched healthy control subjects, after informed consent
was provided. Monocytes from the freshly withdrawn heparin-
ized blood samples were enriched by adherence (7,13).
The monocytes were then incubated in RPMI 1640
containing 5% fetal bovine serum (FBS) (Sigma-Aldrich) and
activated with 1 g/ml lipopolysaccharide (LPS), 3 g/ml
muramyl dipeptide, or 50 g/ml of the yeast cell wall derivative
zymosan (all from Sigma-Aldrich), at 37°C for different lengths
of time (7,13). Supernatants were collected for determination
of IL-1 secretion. The amount of IL-1 secretion in the
monocyte supernatants was determined in triplicate, by
enzyme-linked immunosorbent assay (R&D Systems) (13).
Determination of intracellular reactive oxygen species
(ROS). Monocytes were stimulated with LPS, and 10 M of
dichlorofluorescein diacetate (H2DCF-DA; Molecular Probes)
was added to the cultures 30 minutes before the end of the
incubation. Fluorescence was measured in cell lysates with a
microplate fluorimeter, with excitation at 480 nm and emission
at 530 nm for H2DCF-DA. Data were normalized to the
protein content of cell lysates, as measured by the Lowry
method (17). Duplicate experiments were performed for each
sample.
Determination of cysteine in culture medium. Super-
natants (0.1 ml) from monocytes cultured at 4  10
5/0.5 ml in
24-well plates in RPMI–5% FBS were reacted with 10 mM
5,5-dithiobis-(2-nitrobenzoic acid) (Sigma-Aldrich), and the
absorption was measured at 412 nm. Cysteine (Sigma-Aldrich)
was used as standard (17). Triplicate experiments were per-
formed for each sample.
Real-time PCR. Total RNA was isolated from mono-
cytes using TriPure Isolation Reagent (Roche) and reverse-
transcribed using Superscript III Reverse Transcriptase (In-
vitrogen). Real-time PCR determination of cystine transporter
(xCT) and thioredoxin cDNA was performed as described
previously (15), using SYBR Green ER quantitative PCR
Supermix for the iCycler Reagent (Invitrogen). The specific
primers used were as follows: forward 5-
AAACCCAAGTGGTTCAGACG-3 and reverse 5-
ATCTCAATCCTGGGCAGATG-3 (for xCT), forward 5-
AGCAGATCGAGAGCAAGACT-3 and reverse 5-
CACTCTGAAGCAACATCCTG-3 (for thioredoxin), and
forward 5-ATGGCCTTCCGTGTTCCTAC-3 and reverse
5-GCTTCACCACCTTCTTGATGTC-3 (for GAPDH). Rel-
ative expression of messenger RNA (mRNA) was determined
using the Ct method.
Statistical analysis. The data were statistically ana-
lyzed by one-way analysis of variance, followed by posttest
Bonferroni correction, or by unpaired t-test using GraphPad
software. Differences were considered statistically significant
at P values less than or equal to 0.05.
RESULTS
NLRP12 mutation screening and clinical features
of patients carrying a coding variant. Among a large
panel of individuals affected with autoinflammatory
disorders, 50 patients were selected for molecular
screening of the NLRP12 gene. Since a previous study
identified mutations exclusively in the third exon of the
gene (9) and, similarly, mutations in different regions of
the NLRP3 gene, belonging to the same CATER-
PILLER family, have been detected only occasionally
(18), we decided to limit the mutation screening of
NLRP12 solely to exon 3. A number of common variants
were detected, in addition to 1 missense heterozygous
nucleotide change, c.882CG, leading to the amino acid
Table 1. Conditions of the polymerase chain reaction (PCR)
Fragment
PCR size,
bp Primer
PCR conditions*
Protocol† Enhancer
Fragment A 643 Forward 5-GAGTAGCTGGAACTACAGGC-3,
reverse 5-GCTCATCGAAGCCGTCGATG-3
94°C for 30 minutes, 62°C for 40 minutes,
72°C for 40 minutes (28 cycles)
Fragment B 497 Forward 5-GAAGCTCTTCCAAGGCAGATT-3,
reverse 5-CGAAGCACATGGTGAAGAGA-3
94°C for 30 minutes, 60°C for 40 minutes,
72°C for 40 minutes (30 cycles)
5% DMSO
Fragment C 499 Forward 5-TCTGAGGCAGAAAGGAAGGA-3,
reverse 5-CCCCCTCGTCCAGGATATAG-3
94°C for 30 minutes, 55°C for 40 minutes,
72°C for 40 minutes (35 cycles)
5% DMSO
Fragment D 441 Forward 5-TTCCAGAAGGACATCAACTGTG-3,
reverse 5-CTCCATCTTGGAGGCAATGT-3
94°C for 30 minutes, 55°C for 40 minutes,
72°C for 40 minutes (35 cycles)
5% DMSO
Fragment E 274 Forward 5-CAGCTGCTTGTACGAGATCC-3,
reverse 5-CACGAACCTAAGCAGCCCCA-3
94°C for 30 minutes, 60°C for 40 minutes,
72°C for 40 minutes (30 cycles)
* One hundred nanograms of DNA was amplified in a 25-l reaction containing 10 mM Tris HCl, pH 8.3, 1.5 mM MgCl2,5 0m M KCl, 200 l dNTPs,
and 1.25 units Taq polymerase (TaqGold; Applied Biosystems) with 1 M of each appropriate PCR primer.
†An initial denaturation step at 95°C for 10 minutes and an extension cycle at 72°C for 7 minutes at the end were performed.
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ulations with the online software programs Poliphen and
SIFT (available at http://genetics.bwh.harvard.edu/pph/
and http://blocks.fhcrc.org/sift/SIFT.html, respectively),
we predicted a deleterious effect of this mutation, which
turned out to be located in the highly conserved se-
quence Walker B, considered necessary for ATP binding
and for subsequent activity in the protein (19).
The individual who was found to be a carrier of
the p.Asp294Glu mutation, a 32-year-old woman, came
to our observation for the first time in January 2006 with
a suspected diagnosis of FCAS. Since the age of 20
years, she had experienced recurrent episodes of urticar-
ial rash associated with fever, arthralgias, myalgia, and
headache. The clinical manifestations occurred exclu-
sively during winter time and were exacerbated by cold
exposure. The rash was generally itchy and involved the
face, arms, and trunk. Fever episodes were associated
with elevations in the levels of acute-phase reactants,
with normalization of levels during symptom-free inter-
vals. Episodes occurred for an overall duration of 7–15
days and showed a clinical response to steroid and
antihistamine administration. The patient was found to
be negative for antinuclear antibodies, antineutrophil
cytoplasmic antibodies, and complement consumption.
The skin-ice test and test for allergies consistently
yielded negative results. The patient displayed complete
well-being during the warm season. Prophylactic admin-
istration of low-dose steroids and antihistamines during
the winter time resulted in prevention of the clinical
manifestations. No hearing loss or ocular involvement
(papilledema, uveitis) were observed.
The p.Asp294Glu mutation was also identified in
3 other family members (Figure 1). The proband’s father
(patient II-9 in Figure 1), a 61-year-old otherwise-
healthy man, reported having a clear sensitivity to cold
exposure since childhood, with arthralgias and myalgia
variably associated with a mild and transient urticarial
rash. These episodes were generally well tolerated and
did not significantly influence his daily activities. He was
treated at demand with nonsteroidal antiinflammatory
drugs (NSAIDs) to control the symptoms. Clinical man-
ifestations were generally prevented by avoiding expo-
sure to the cold. In fact, a clear exacerbation of the
clinical manifestations was observed after cold exposure
(i.e., air conditioning or entry into the frozen food
section of the supermarket). No unexplained fever epi-
sodes were reported. Whenever tested, the levels of
acute-phase reactants were in the normal range. How-
ever, due to the modest severity and short duration of
his clinical manifestations, the patient was never tested
during the presence of cold-induced symptoms. More-
over, a cold-provocation test was not performed, due to
the patient’s refusal. Results of allergy tests and the
skin-ice test were negative. No hearing loss or cutaneous
manifestations were present.
A 78-year-old woman, aunt of the proband, was
also affected (patient II-4 in Figure 1). Since infancy, she
had experienced arthralgias and myalgia, variably asso-
ciated with an urticarial rash, with limitation of daily
activities. Low-grade fever and elevation in the levels of
acute-phase reactants were also reported. At the age of
38 years, the patient developed an optic neuritis, which
was treated with steroids. Similar to the other affected
family members, her clinical manifestations were
present during the winter time, with complete well-being
during the warm season. Evident sensitivity to cold
exposure (“frozen food section” symptoms) was also
Figure 1. Genealogy tree of the Italian Caucasian family identified as having a
recurrence of the p.D294E substitution (represented by “m”) in the NLRP12 gene.
Each symbol represents an individual female (circle) or male (square) family
member, with Roman numerals indicating the generational level. Arrow indicates the
proband, large solid symbols indicate individuals with clinical manifestations, small
solid symbol indicates abortion, and slashes indicate death.
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vasculitis was suspected. The clinical manifestations
were partially controlled by NSAIDs and by variable
courses of steroids at the time of exacerbation of the
clinical manifestations.
The fourth carrier of the p.Asp294Glu NLRP12
mutation within the family was a 67-year-old man, uncle
of the proband (patient II-7 in Figure 1). At variance
with the other affected family members, he denied ever
having any evident clinical manifestations associated
with cold exposure. Conversely, an urticarial-like rash
was observed, in conjunction with episodes of fever,
which was, according to the patient’s judgment, mainly
associated with intercurrent viral or bacterial infections.
No musculoskeletal manifestations, hearing loss, or oc-
ular manifestations were reported. The patient died of
myocardial infarction soon after the identification of the
molecular defect. Another 6 asymptomatic members of
the family were screened and were found to carry WT
NLRP12.
In vitro analysis of the NLRP12 mutation effect
on NF-B activity. In the original report describing, for
the first time, patients affected with NLRP12-related
periodic fever, in vitro analysis of transfected cells
showed that the mutations found were associated with
an impairment of the NLRP12-mediated inhibitor activ-
ity on the NF-B pathway (9). In particular, the trun-
cated p.Arg284X and the frameshift Val635ThrfsX12
NLRP12 mutations were demonstrated to be function-
ally associated with high levels of NF-B activity, thus
accounting for the autoinflammatory phenotype. We
therefore decided to apply the same approach, based on
the cotransfection of a luciferase NF-B promoter re-
porter construct with either mutant or WT NLRP12
expression plasmids in HEK 293 cells, to test the
p.Asp294Glu NLRP12 mutation.
The NF-B–dependent luciferase activity in-
duced by overexpression of IRAK-1 or MyD88 was
analyzed in cotransfection experiments with either WT
or mutant NLRP12 plasmids (Figures 2A and B). Con-
tradicting the results expected based on the in silico
prediction, the p.Asp294Glu-mutated protein main-
tained the same NF-B–inhibitory activity as that shown
by WT NLRP12, even when increasing amounts of the
expression plasmids were used (Figures 3A and B).
Surprisingly, at variance with previously reported find-
ings (9), the p.Arg284X nonsense mutation was unable
to prevent the inhibitory effect of WT NLRP12. More-
over, in contrast to the findings already reported (9) but
consistent with other previous data (12), we could not
observe any inhibitory effect of WT NLRP12 on NF-B
Figure 2. Results of luciferase assays in HEK 293 cells, testing the
inhibitory capability of wild-type (WT) and mutant NLRP12 (N12)
proteins on NF-B signaling. A and B, Interleukin-1 receptor–
associated kinase 1 (IRAK-1) (A) or myeloid differentiation factor 88
(MyD88) (B) was transfected to induce NF-B activity. Cotransfec-
tions included NLRP12 WT or mutant (p.D294E missense or
p.Arg284X nonsense) variants, pcDNA3.1 empty vector (EV), or a
construct containing NF-B binding sites upstream of the luciferase
reporter gene (NF-luc), along with adequate combinations of plasmid
as controls. Bars show the mean  SD of triplicate experiments. C,
Western blotting of lysates from the same cells as in A and B was
performed to confirm expression of the NLRP-12 proteins cloned with
the V5 epitope. The antibody -actin was used to verify equal amounts
of the different lysates.
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p.Asp294Glu mutation was not tested in this experimen-
tal design. To rule out the possibility that the absence of
effects of the mutated NLRP12 on NF-B activity was
due to unsuitability of the cell model used (human
embryonic kidney cells), the same experiment was re-
peated in the monocytic cell line THP-1. Even in these
cells, however, the same absence of effect was observed
(results not shown).
Ex vivo analysis of NF-B activity in patients
with the NLRP12 mutation. To further investigate the
role of the p.Asp294Glu gene variant in the cold-
induced autoinflammatory clinical features recurring in
the proband’s family, we undertook an analysis of the
expression of the active form of NF-B in primary cells
from family members with the mutation. In particular,
we analyzed the expression of NF-B in 3 family mem-
bers carrying the p.Asp294Glu NLRP12 mutation, all
of whom, at the moment of the study, were asympto-
matic.
Patients with this NLRP12 mutation did not show
increased basal levels of p65-induced NF-B activity as
compared with that in healthy controls (Figure 4).
Consistently, when monocytes were stimulated with
TNF, a variable response was observed in both the
patients and the healthy controls. In any case, with the
exception of patient II-4, whose cells displayed only a
modest increment of NF-B activity after TNF stimu-
lation, the level of increase in p65-induced NF-B
activity in the other 2 patients with the NLRP12 muta-
tion was comparable to that observed in healthy controls
(Figure 4).
Figure 3. Dose effects of interleukin-1 receptor–associated kinase 1
(IRAK-1) (A), myeloid differentiation factor 88 (MyD88) (B),o r
p65-RelA (C) expression vectors transfected to induce NF-B activity,
as determined in luciferase assays using HEK 293 cells. Increasing
amounts of both wild-type (WT) and mutant NLRP12 (N12) displayed
increasing inhibitory effects on NF-B signaling, as indicated by
reductions in the relative luciferase activity (y-axis). Bars show the
mean  SD of triplicate experiments. EV  pcDNA3.1 empty vector.
Figure 4. NF-B activation induced by p65 in monocytes from 3
patients (Pt) with the p.D294E mutation and 5 age-matched healthy
controls (Ctr). Monocytes were either left unstimulated or stimulated
with 10 ng/ml tumor necrosis factor  (TNF) for 24 hours. The Active
Motif TransAM NF-B p65 kit was used to assess NF-B activity.
OD  optical density.
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stress response in monocytes from patients with the
NLRP12 mutation. Since NLRP12 has a close structural
homology with NLRP3, we investigated whether, as in
patients with CAPS, IL-1 hypersecretion in response to
Toll-like receptor (TLR) stimulation may also represent
the crucial pathogenic event in patients carrying the
p.Asp294Glu NLRP12 mutation. As shown in Figure 5A,
NLRP12-mutated monocytes from the 3 patients, after
stimulation for 18 hours with the TLR-4 ligand LPS,
secreted levels of IL-1 that were comparable to those in
healthy monocytes, but significantly lower than those
secreted by NLRP3-mutated monocytes. Triggering of
other TLRs by different PAMPs provided similar re-
sults.
Interestingly, the kinetics of IL-1 secretion by
NLRP12-mutated monocytes from patients III-12 and
II-4 were accelerated as compared with that in healthy
monocytes (Figure 5B); at 6 hours after LPS exposure,
the level of secreted IL-1 was more than twice that
secreted by controls. A similar, although more dramatic,
acceleration of IL-1 secretion, with early achievement
of a plateau, was observed in monocytes from a patient
with CINCA syndrome (Figure 5B). In contrast, patient
II-9, who presented with the mildest clinical manifesta-
tions, did not exhibit this pattern.
Redox remodeling is strongly implicated in the
process of IL-1 maturation and secretion in healthy
conditions (17). TLR triggering induces ROS generation
followed by an antioxidant response characterized by
up-regulation of the cystine transporter (xCT) and of the
oxidoreductase thioredoxin. This up-regulation results in
increased uptake of cystine, intracellular conversion to
cysteine, and release of reduced cysteine. Interestingly,
we have recently shown that the accelerated kinetics of
IL-1 secretion by CAPS monocytes is related to redox
alterations (20).
Monocytes from patients with CAPS display an
unbalanced redox state in resting conditions and an
impaired redox response to TLR-mediated oxidative
stress, with earlier up-regulation and rapid exhaustion of
the antioxidant response. Namely, CAPS monocytes
produce more ROS than has been found in control
monocytes in basal conditions. The increased level of
ROS is responsible for the activation, in resting cells, of
antioxidant systems that, after TLR triggering, increase
and collapse earlier than in healthy monocytes. This
deranged redox response is responsible for the acceler-
ated IL-1 secretion and the earlier achievement of the
plateau after LPS stimulation (20).
Thus, we investigated the presence of redox
alterations in NLRP12-mutated monocytes. As shown in
Figure 5C, unstimulated NLRP12-mutated monocytes,
like CAPS cells, produced more ROS than healthy
Figure 5. Accelerated kinetics of interleukin-1 (IL-1) secretion and
associated redox alterations in NLRP12-mutated monocytes. In these
experiments, monocytes from 5–7 healthy donors (HD), a representa-
tive patient with chronic infantile neurologic, cutaneous, articular
syndrome (CINCA syndrome), and 3 patients with the NLRP12
mutation were assessed. A, Secretion of IL-1 was determined by
enzyme-linked immunosorbent assay in monocytes cultured for 18
hours alone or with 1 g/ml lipopolysaccharide (LPS), 3 g/ml
muramyl dipeptide (MDP), or 50 g/ml zymosan (Zym). NS  not
significant. B, The kinetics of IL-1 secretion were assessed after
exposure of the monocytes to LPS for 3, 6, or 18 hours. C, Intracellular
levels of reactive oxygen species (ROS) were determined in monocytes
cultured for 1 hour alone or with LPS, with results expressed as relative
fluorescence units (RFU). D, Extracellular cysteine levels were deter-
mined in 18-hour supernatants of monocytes cultured alone or with
LPS. Statistical comparisons were not performed for patients II-9 and
II-4 due to an inadequate number of experiments. E and F, Real-time
polymerase chain reaction was used to analyze the mean  SD fold
change in levels of cystine transporter (xCT) (E) and thioredoxin (F)
mRNA after 2-hour or 4-hour LPS treatment in monocytes from the 3
patients with the NLRP12 mutation and 5 healthy donors, relative to
that in untreated monocytes. Bars in A, B, and D show the mean  SD
of triplicate experiments; bars in C show the mean  SD of duplicate
experiments.   P  0.05;   P  0.01;   P  0.001.
836 BORGHINI ET ALmonocytes. Antioxidant defenses were also activated, as
indicated by the higher release of reduced cysteine in the
absence of TLR triggering (Figure 5D).
Similar to that in CAPS cells, the antioxidant
response to LPS exhausted earlier in NLRP12-mutated
monocytes. In normal monocytes, up-regulation of the
cystine transporter xCT and of thioredoxin was detect-
able at low levels after 2 hours of LPS exposure and
strongly increased after 4 hours. In contrast, in NLRP12-
mutated monocytes, xCT and thioredoxin mRNA were
induced earlier, but the levels increased to a lesser
extent compared with that in controls (Figures 5E and
F). The rapid exhaustion of the antioxidant systems was
confirmed by the decrease in cysteine externalization
that was observed following long-term stimulation with
LPS (Figure 5D).
Remarkably, monocytes from patient III-12, who
had the most severe phenotype and in whom the most
accelerated kinetics of IL-1 secretion were observed
(Figure 5B), also exhibited the strongest redox derange-
ment, with the highest basal levels of ROS (Figure 5C)
and of cysteine release in resting conditions (Figure 5D)
and the most rapid up-regulation and exhaustion of
thioredoxin and xCT upon stimulation (Figures 5E and
F). In contrast, monocytes from patient II-9, who had
milder clinical manifestations and in whom the kinetics
of IL-1 secretion were comparable to those in controls,
exhibited milder alterations of the redox state, although
a collapse of the antioxidant response was still observed
in this case (Figures 5D–F).
DISCUSSION
A previous report identified both a nonsense and
a frameshift mutation in the sequence of a member of
the NLRP family, NLRP12, in 2 families in whom at least
2 members of the family had a syndrome resembling
either FCAS or MWS (9). On the basis of this observa-
tion, we selected a number of patients with a clinical
phenotype suggestive of CAPS and who were negative
for mutations of the NLRP3 sequence, for NLRP12
mutation screening. The heterozygous amino acid sub-
stitution p.Asp294Glu was identified in a patient af-
fected with a clinical phenotype consistent with a cold-
induced autoinflammatory disease, which was found to
be absent in a population sample of control chromo-
somes of the same origin.
As already reported by Jeru et al, the clinical
phenotype of the family members other than the pro-
bands in their study was rather variable (9). In the family
members in our study, the p.Asp294Glu mutation was
found to mostly segregate with a particular sensitivity to
cold exposure (especially arthralgias and myalgia), even
in the absence of urticarial rash, fever, or elevation in the
levels of acute-phase reactants. In any case, the clinical
manifestations presented by the carriers were generally
mild, although quality of life was affected, especially
during the winter season in patient II-4 and in the
proband. Such phenotypic heterogeneity is frequently
observed in autoinflammatory syndromes, as in the case
of NALP3 mutations such as V198M and V200M, which
can be associated with CAPS of different severity
(18,21). Therefore, we can conclude that wide variability
in the expression of the symptoms is a feature of both
NLRP3- and NLRP12-related disorders, presenting phe-
notypic variability even among members of the same
family (8,21).
The missense mutation p.Asp294Glu affects an
evolutionarily conserved domain, including that at posi-
tion 294, which is fundamental for ATP binding and
does not allow any change, even a conservative change,
in phenotype. This was confirmed in our study not only
by the associated disease phenotypes identified in the
Caucasian family, but also by the simulations using
Polyphen and SIFT software.
To further confirm this finding, we cloned the
WT NLRP12 cDNA and generated the p.Asp294Glu
mutant version of the construct, to study in vitro their
effect on the NF-B canonical pathway. In contrast to
the findings in the previous study by Jeru et al (9),
however, no clear reduction of the inhibitory properties
of the p.Asp294Glu mutant of NLRP12 on NF-B
signaling was observed, as shown by transfection exper-
iments using the IRAK-1 and MyD88 expression vec-
tors. In addition, we could not confirm the decreased
inhibitory effect reported for a truncated NLRP-12
protein (9), a discrepancy difficult to explain on the basis
of the data obtained under identical experimental con-
ditions, although not with identical constructs.
Finally, we could not test the mutant NLRP12
effect on p65-induced NF-B activation. Indeed, in
accordance with the findings from a previous biochem-
ical study in which the inhibitory activity of NLRP12 on
NF-B signaling acted on the initial steps of both the
TLR and TNF receptor pathways (12), transfection of
NLRP12 constructs could not inhibit the activity of
NF-B induced by forced expression of p65.
Our experimental approach was designed to in-
vestigate the effect of NLRP12 only on the canonical
NF-B pathway, and this allowed us to exclude such an
involvement. However, we cannot exclude the possibility
that NLRP12 has a role in suppressing the noncanonical
RECURRENCE OF AN NLRP12 MUTATION IN FCAS 837NF-B/p100 processing pathway, a mechanism by which
the p.Asp294Glu mutation may contribute to the main-
tenance of high levels of NF-B activation. This again
raises the issue previously discussed by Jeru et al (9), in
which the reported results were consistent with a role of
not only WT NLRP12 in the canonical NF-B pathway
but also its mutant NLRP12–mediated impairment. In
any case, according to Ye et al, an impairment of the
ATP binding domain would reduce the antinflammatory
activity of NLRP12 by affecting both the canonical and
the noncanonical NF-B activating pathways (22). This
suggests that NLRP12 may exert its inhibitory effect
through a still-unknown, NF-B–independent pathway.
Our results from in vitro studies were confirmed
by the assessment of NF-B activity levels on patient
monocytes, which displayed a response to TNF stimu-
lation that was comparable to that in healthy control
cells. With the aim of identifying alternative pathogenic
mechanisms, we therefore analyzed whether NLRP12
variants could affect the pattern of secretion of IL-1,a s
already described in patients with NLRP3 mutations.
The analysis of IL-1 secretion by NLRP12-mutated
monocytes revealed that, although the global level of the
secreted cytokine was comparable to that in healthy
monocytes, the kinetics of secretion were accelerated.
An accelerated secretion of IL-1 was also observed in
CAPS monocytes and was related to a deranged basal
redox state and redox response to TLR triggering (20).
Interestingly, the same redox signature, characterized by
higher basal levels of both ROS and antioxidants and
faster up-regulation of the antioxidant systems upon
TLR triggering, was shared by monocytes from patients
with the NLRP12 mutation. These data confirm a func-
tional relationship between the kinetics of IL-1 secre-
tion and redox remodeling.
The major implication of our findings is that,
whereas in healthy monocytes, IL-1 secretion reaches a
plateau after many hours of exposure to PAMPs, when
mechanisms aimed at down-modulating IL-1 activity,
such as secretion of the IL-1 receptor antagonist (IL-
1Ra), are fully operating (23) in NLRP3- and NLRP12-
mutated monocytes, IL-1 reaches the peak of secretion
earlier, when IL-1Ra production has not yet started.
Thus, a weak TLR stimulation will trigger strong signs of
inflammation in patients with the mutations, since IL-1
will be fully secreted soon after TLR engagement, but
well before IL-1Ra production.
In patients with CAPS, the concomitance of
redox alterations (which accelerate the kinetics of IL-1
secretion) and gain-of-function NLRP3 mutations
(which increase the amount of IL-1 secretion) may act
in cooperation to worsen the CAPS phenotype. It is
tempting to speculate that in patients carrying NLRP12
mutations, the mild autoinflammatory phenotype, char-
acterized by weak clinical manifestations, is due to the
accelerated kinetics of IL-1 secretion, in the absence of
an overall increased amount of the secreted cytokine.
The degree of redox alterations would then account for
the clinical manifestations of variable entities. Support
for this hypothesis comes from the observation that the
strongest redox derangement and the fastest secretion of
IL-1 were observed in the proband, who displayed the
worst clinical signs, whereas monocytes from the father,
who presented with a mild phenotype, had milder redox
alterations and did not exhibit accelerated IL-1 secre-
tion.
Since neither redox nor the kinetics of secretion
are altered in monocytes from patients with nonmono-
genic juvenile idiopathic arthritis (20), our results sug-
gest that the chronic derangement of the redox state and
response, leading to accelerated IL-1 secretion, is not a
common feature of chronic inflammatory diseases, but
rather, is a consequence of mutations of NLRP3 and
NLRP12. It remains to be seen whether mutations of
genes responsible for other autoinflammatory syn-
dromes that respond to IL-1 inhibitors, such as TNF
receptor–associated periodic syndrome, pyogenic arthri-
tis, pyoderma gangrenosum, and acne syndrome, and
hyperimmunoglobulinemia D with periodic fever syn-
drome, are also associated with the same redox alter-
ations linked to accelerated IL-1 secretion in mono-
cytes as we observed in patients with NLRP3 and
NLRP12 mutations.
Thus, the present study showed that the NLRP12
mutation segregating in an Italian Caucasian family was
responsible for the associated mild CAPS-like pheno-
type, and therefore accounted for a dominant inheri-
tance, characterized by variable expressivity and reduced
penetrance. Although the pathogenesis of NLRP12 mu-
tations has not been completely elucidated, we propose
that a deregulation of IL-1 secretion due to an altered
redox state and stress response may play a relevant role.
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